Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REPLIGEN CORPORATION

(RGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Repligen Releases Inaugural Sustainability Report

11/08/2021 | 08:56am EST

WALTHAM, Mass. - Repligen Corporation (NASDAQ: RGEN) released its inaugural sustainability report, available on the Company's website. Repligen's 2020 Sustainability Report provides an overview of the Company's environmental, social and governance (ESG) performance in 2020 and into 2021, and provides disclosures aligned to three key reporting frameworks; the Value Reporting Foundation's SASB Medical Equipment and Supplies Standard, the Global Reporting Initiative (GRI) Standards Core option, and the United Nations (UN) Sustainable Development Goals (SDGs) as informed by the Company's materiality assessment. As a participant of the United Nations Global Compact (UNGC) since July 2020, this report also serves to fulfill Repligen's first Communication on Progress (COP) commitment.

The report is built on four pillars that reflect Repligen's ESG priorities - Principles, People, Product and Planet - where related initiatives and achievements are highlighted.

Tony J. Hunt, President and CEO of Repligen said, 'The release of our first sustainability report is an important achievement for the Company and sets a strong foundation for future progress. It underscores our multi-stakeholder approach to ESG, and it is our hope that its contents demonstrate our strong commitment to corporate responsibility and transparency, and our ambition as we increasingly embed sustainability into our daily business decisions and operations.'

Karen A. Dawes, Repligen's Chairperson of the Board and Chair of the Nominating & Corporate Governance Committee said, 'This inaugural sustainability report highlights the steps we are taking to embrace ESG and to commit to programs that heighten our positive, and minimize our negative impacts on society and our environment, with a view toward a stronger global economy, more equitable societies and a healthier planet.'

Repligen's sustainability report is available at https://sustainability.repligen.com

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Hampshire, New Jersey and New York), and outside of the U.S. we have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at www.repligen.com. Follow us on LinkedIn and Twitter.

Contact:

Sondra S. Newman

Global Head of Investor Relations

T: (781) 419-1881

E: investors@repligen.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about REPLIGEN CORPORATION
01/12Repligen Seeks Acquisitions
CI
01/04REPLIGEN CORP : Change in Directors or Principal Officers, Financial Statements and Exhibi..
AQ
01/04Repligen Corporation Promotes James Bylund to the Chief Operating Officer and Principal..
CI
2021Repligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference
AQ
2021REPLIGEN CORP : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
2021Repligen Corporation acquired Bio-Flex Solutions, L.L.C. / Newton T & M Corp.
CI
2021INSIDER SELL : Repligen
MT
2021INSIDER SELL : Repligen
MT
2021Repligen Corporation to Present at Upcoming Investor Conferences
GL
2021Repligen Releases Inaugural Sustainability Report
AQ
More news
Analyst Recommendations on REPLIGEN CORPORATION
More recommendations
Financials (USD)
Sales 2021 662 M - -
Net income 2021 128 M - -
Net cash 2021 431 M - -
P/E ratio 2021 79,0x
Yield 2021 -
Capitalization 9 790 M 9 790 M -
EV / Sales 2021 14,1x
EV / Sales 2022 11,5x
Nbr of Employees -
Free-Float -
Chart REPLIGEN CORPORATION
Duration : Period :
Repligen Corporation Technical Analysis Chart | RGEN | US7599161095 | MarketScreener
Technical analysis trends REPLIGEN CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 177,07 $
Average target price 312,56 $
Spread / Average Target 76,5%
EPS Revisions
Managers and Directors
Tony J. Hunt President, Chief Executive Officer & Director
Jon K. Snodgres Chief Financial Officer
Karen A. Dawes Chairman
Ralf Kuriyel Senior Vice President-Research & Development
James R. Bylund Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
REPLIGEN CORPORATION-31.45%9 790
ABBOTT LABORATORIES-14.42%206 551
MEDTRONIC PLC-0.26%138 731
BECTON, DICKINSON AND COMPANY0.96%71 600
HOYA CORPORATION-18.59%44 518
BAXTER INTERNATIONAL INC.-1.41%42 374